EMEA (Europe, Middle East and Africa) Neuroendocrine Tumor Drug Market Report 2018

January 2018 | 110 pages | ID: E6F9456F755EN
QYResearch

Abstracts

In this report, the EMEA Neuroendocrine Tumor Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Neuroendocrine Tumor Drug for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Neuroendocrine Tumor Drug market competition by top manufacturers/players, with Neuroendocrine Tumor Drug sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Eisai
• Exelixis, Inc.
• Foresee Pharmaceuticals, LLC
• Hutchison MediPharma Limited
• Intezyne, Inc
• INVENT Pharmaceuticals, Inc.
• Ipsen S.A.
• Jiangsu Hengrui Medicine Co., Ltd.
• Karyopharm Therapeutics, Inc.
• Lexicon Pharmaceuticals, Inc.
• Midatech Pharma Plc.
• Millennium Pharmaceuticals, Inc.
• MolMed S.p.A.
• Northwest Biotherapeutics, Inc.
• Novartis AG
• OctreoPharm Sciences GmbH
• OXiGENE, Inc.

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• mTOR protein inhibitors
• Tyrosine kinase 3 inhibitors
• Somatostatin receptor antagonists
• Growth hormone releasing factor antagonists
• Somatostatin receptor agonists
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospital
• Clinic
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Neuroendocrine Tumor Drug Market Report 2017

1 NEUROENDOCRINE TUMOR DRUG OVERVIEW

1.1 Product Overview and Scope of Neuroendocrine Tumor Drug
1.2 Classification of Neuroendocrine Tumor Drug
  1.2.1 EMEA Neuroendocrine Tumor Drug Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Neuroendocrine Tumor Drug Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 mTOR protein inhibitors
  1.2.4 Tyrosine kinase 3 inhibitors
  1.2.5 Somatostatin receptor antagonists
  1.2.6 Growth hormone releasing factor antagonists
  1.2.7 Somatostatin receptor agonists
  1.2.8 Others
1.3 EMEA Neuroendocrine Tumor Drug Market by Application/End Users
  1.3.1 EMEA Neuroendocrine Tumor Drug Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Hospital
  1.3.3 Clinic
  1.3.4 Others
1.4 EMEA Neuroendocrine Tumor Drug Market by Region
  1.4.1 EMEA Neuroendocrine Tumor Drug Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Neuroendocrine Tumor Drug (2012-2022)
  1.5.1 EMEA Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Neuroendocrine Tumor Drug Revenue and Growth Rate (2012-2022)

2 EMEA NEUROENDOCRINE TUMOR DRUG COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Neuroendocrine Tumor Drug Market Competition by Players/Manufacturers
  2.1.1 EMEA Neuroendocrine Tumor Drug Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Neuroendocrine Tumor Drug Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Neuroendocrine Tumor Drug Sale Price by Players (2012-2017)
2.2 EMEA Neuroendocrine Tumor Drug (Volume and Value) by Type/Product Category
  2.2.1 EMEA Neuroendocrine Tumor Drug Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Neuroendocrine Tumor Drug Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Neuroendocrine Tumor Drug Sale Price by Type (2012-2017)
2.3 EMEA Neuroendocrine Tumor Drug (Volume) by Application
2.4 EMEA Neuroendocrine Tumor Drug (Volume and Value) by Region
  2.4.1 EMEA Neuroendocrine Tumor Drug Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Neuroendocrine Tumor Drug Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Neuroendocrine Tumor Drug Sales Price by Region (2012-2017)

3 EUROPE NEUROENDOCRINE TUMOR DRUG (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Neuroendocrine Tumor Drug Sales and Value (2012-2017)
  3.1.1 Europe Neuroendocrine Tumor Drug Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Neuroendocrine Tumor Drug Revenue and Growth Rate (2012-2017)
3.2 Europe Neuroendocrine Tumor Drug Sales and Market Share by Type
3.3 Europe Neuroendocrine Tumor Drug Sales and Market Share by Application
3.4 Europe Neuroendocrine Tumor Drug Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Neuroendocrine Tumor Drug Sales Volume by Countries (2012-2017)
  3.4.2 Europe Neuroendocrine Tumor Drug Revenue by Countries (2012-2017)
  3.4.3 Germany Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)
  3.4.4 France Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)
  3.4.5 UK Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)
  3.4.6 Russia Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)
  3.4.7 Italy Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)

4 MIDDLE EAST NEUROENDOCRINE TUMOR DRUG (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Neuroendocrine Tumor Drug Sales and Value (2012-2017)
  4.1.1 Middle East Neuroendocrine Tumor Drug Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Neuroendocrine Tumor Drug Revenue and Growth Rate (2012-2017)
4.2 Middle East Neuroendocrine Tumor Drug Sales and Market Share by Type
4.3 Middle East Neuroendocrine Tumor Drug Sales and Market Share by Application
4.4 Middle East Neuroendocrine Tumor Drug Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Neuroendocrine Tumor Drug Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Neuroendocrine Tumor Drug Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)
  4.4.4 Israel Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)
  4.4.5 UAE Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)
  4.4.6 Iran Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)

5 AFRICA NEUROENDOCRINE TUMOR DRUG (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Neuroendocrine Tumor Drug Sales and Value (2012-2017)
  5.1.1 Africa Neuroendocrine Tumor Drug Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Neuroendocrine Tumor Drug Revenue and Growth Rate (2012-2017)
5.2 Africa Neuroendocrine Tumor Drug Sales and Market Share by Type
5.3 Africa Neuroendocrine Tumor Drug Sales and Market Share by Application
5.4 Africa Neuroendocrine Tumor Drug Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Neuroendocrine Tumor Drug Sales Volume by Countries (2012-2017)
  5.4.2 Africa Neuroendocrine Tumor Drug Revenue by Countries (2012-2017)
  5.4.3 South Africa Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Neuroendocrine Tumor Drug Sales and Growth Rate (2012-2017)

6 EMEA NEUROENDOCRINE TUMOR DRUG MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Eisai
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Neuroendocrine Tumor Drug Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Eisai Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Exelixis, Inc.
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Neuroendocrine Tumor Drug Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Foresee Pharmaceuticals, LLC
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Neuroendocrine Tumor Drug Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Hutchison MediPharma Limited
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Neuroendocrine Tumor Drug Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Intezyne, Inc
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Neuroendocrine Tumor Drug Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 INVENT Pharmaceuticals, Inc.
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Neuroendocrine Tumor Drug Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Ipsen S.A.
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Neuroendocrine Tumor Drug Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Jiangsu Hengrui Medicine Co., Ltd.
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Neuroendocrine Tumor Drug Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Karyopharm Therapeutics, Inc.
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Neuroendocrine Tumor Drug Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Lexicon Pharmaceuticals, Inc.
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Neuroendocrine Tumor Drug Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Midatech Pharma Plc.
6.12 Millennium Pharmaceuticals, Inc.
6.13 MolMed S.p.A.
6.14 Northwest Biotherapeutics, Inc.
6.15 Novartis AG
6.16 OctreoPharm Sciences GmbH
6.17 OXiGENE, Inc.

7 NEUROENDOCRINE TUMOR DRUG MANUFACTURING COST ANALYSIS

7.1 Neuroendocrine Tumor Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Neuroendocrine Tumor Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Neuroendocrine Tumor Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Neuroendocrine Tumor Drug Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA NEUROENDOCRINE TUMOR DRUG MARKET FORECAST (2017-2022)

11.1 EMEA Neuroendocrine Tumor Drug Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Neuroendocrine Tumor Drug Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Neuroendocrine Tumor Drug Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Neuroendocrine Tumor Drug Price and Trend Forecast (2017-2022)
11.2 EMEA Neuroendocrine Tumor Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Neuroendocrine Tumor Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Neuroendocrine Tumor Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Neuroendocrine Tumor Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Neuroendocrine Tumor Drug Sales Forecast by Type (2017-2022)
11.7 EMEA Neuroendocrine Tumor Drug Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Neuroendocrine Tumor Drug
Figure EMEA Neuroendocrine Tumor Drug Sales Volume (K Pcs) by Type (2012-2022)
Figure EMEA Neuroendocrine Tumor Drug Sales Volume Market Share by Type (Product Category) in 2016
Figure mTOR protein inhibitors Product Picture
Figure Tyrosine kinase 3 inhibitors Product Picture
Figure Somatostatin receptor antagonists Product Picture
Figure Growth hormone releasing factor antagonists Product Picture
Figure Somatostatin receptor agonists Product Picture
Figure Others Product Picture
Figure EMEA Neuroendocrine Tumor Drug Sales Volume (K Pcs) by Application (2012-2022)
Figure EMEA Sales Market Share of Neuroendocrine Tumor Drug by Application in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Others Examples
Table Key Downstream Customer in Others
Figure EMEA Neuroendocrine Tumor Drug Market Size (Million USD) by Region (2012-2022)
Figure Europe Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Neuroendocrine Tumor Drug Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Neuroendocrine Tumor Drug Revenue (Million USD) Status and Forecast by Countries
Figure Africa Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Neuroendocrine Tumor Drug Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Neuroendocrine Tumor Drug Sales Volume and Growth Rate (2012-2022)
Figure EMEA Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Neuroendocrine Tumor Drug Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table EMEA Neuroendocrine Tumor Drug Sales Volume (K Pcs) of Major Players (2012-2017)
Table EMEA Neuroendocrine Tumor Drug Sales Share by Players (2012-2017)
Figure 2016 Neuroendocrine Tumor Drug Sales Share by Players
Figure 2017 Neuroendocrine Tumor Drug Sales Share by Players
Figure EMEA Neuroendocrine Tumor Drug Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Neuroendocrine Tumor Drug Revenue (Million USD) by Players (2012-2017)
Table EMEA Neuroendocrine Tumor Drug Revenue Share by Players (2012-2017)
Table 2016 EMEA Neuroendocrine Tumor Drug Revenue Share by Players
Table 2017 EMEA Neuroendocrine Tumor Drug Revenue Share by Players
Table EMEA Neuroendocrine Tumor Drug Sale Price (USD/Pcs) by Players (2012-2017)
Table EMEA Neuroendocrine Tumor Drug Sales (K Pcs) and Market Share by Type (2012-2017)
Table EMEA Neuroendocrine Tumor Drug Sales Share by Type (2012-2017)
Figure Sales Market Share of Neuroendocrine Tumor Drug by Type (2012-2017)
Figure EMEA Neuroendocrine Tumor Drug Sales Market Share by Type (2012-2017)
Table EMEA Neuroendocrine Tumor Drug Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Neuroendocrine Tumor Drug Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Neuroendocrine Tumor Drug by Type in 2016
Table EMEA Neuroendocrine Tumor Drug Sale Price (USD/Pcs) by Type (2012-2017)
Table EMEA Neuroendocrine Tumor Drug Sales (K Pcs) and Market Share by Application (2012-2017)
Table EMEA Neuroendocrine Tumor Drug Sales Share by Application (2012-2017)
Figure Sales Market Share of Neuroendocrine Tumor Drug by Application (2012-2017)
Figure EMEA Neuroendocrine Tumor Drug Sales Market Share by Application in 2016
Table EMEA Neuroendocrine Tumor Drug Sales (K Pcs) and Market Share by Region (2012-2017)
Table EMEA Neuroendocrine Tumor Drug Sales Share by Region (2012-2017)
Figure Sales Market Share of Neuroendocrine Tumor Drug by Region (2012-2017)
Figure EMEA Neuroendocrine Tumor Drug Sales Market Share in 2016
Table EMEA Neuroendocrine Tumor Drug Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Neuroendocrine Tumor Drug Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Neuroendocrine Tumor Drug by Region (2012-2017)
Figure EMEA Neuroendocrine Tumor Drug Revenue Market Share Regions in 2016
Table EMEA Neuroendocrine Tumor Drug Sales Price (USD/Pcs) by Region (2012-2017)
Figure Europe Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Europe Neuroendocrine Tumor Drug Revenue and Growth Rate (2012-2017)
Table Europe Neuroendocrine Tumor Drug Sales (K Pcs) by Type (2012-2017)
Table Europe Neuroendocrine Tumor Drug Market Share by Type (2012-2017)
Figure Europe Neuroendocrine Tumor Drug Market Share by Type in 2016
Table Europe Neuroendocrine Tumor Drug Sales (K Pcs) by Application (2012-2017)
Table Europe Neuroendocrine Tumor Drug Market Share by Application (2012-2017)
Figure Europe Neuroendocrine Tumor Drug Market Share by Application in 2016
Table Europe Neuroendocrine Tumor Drug Sales (K Pcs) by Countries (2012-2017)
Table Europe Neuroendocrine Tumor Drug Sales Market Share by Countries (2012-2017)
Figure Europe Neuroendocrine Tumor Drug Sales Market Share by Countries (2012-2017)
Figure Europe Neuroendocrine Tumor Drug Sales Market Share by Countries in 2016
Table Europe Neuroendocrine Tumor Drug Revenue (Million USD) by Countries (2012-2017)
Table Europe Neuroendocrine Tumor Drug Revenue Market Share by Countries (2012-2017)
Figure Europe Neuroendocrine Tumor Drug Revenue Market Share by Countries (2012-2017)
Figure Europe Neuroendocrine Tumor Drug Revenue Market Share by Countries in 2016
Figure Germany Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure France Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure UK Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Russia Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Italy Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Benelux Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Neuroendocrine Tumor Drug Sales (K Pcs) by Type (2012-2017)
Table Middle East Neuroendocrine Tumor Drug Market Share by Type (2012-2017)
Figure Middle East Neuroendocrine Tumor Drug Market Share by Type (2012-2017)
Table Middle East Neuroendocrine Tumor Drug Sales (K Pcs) by Applications (2012-2017)
Table Middle East Neuroendocrine Tumor Drug Market Share by Applications (2012-2017)
Figure Middle East Neuroendocrine Tumor Drug Sales Market Share by Application in 2016
Table Middle East Neuroendocrine Tumor Drug Sales Volume (K Pcs) by Countries (2012-2017)
Table Middle East Neuroendocrine Tumor Drug Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Neuroendocrine Tumor Drug Sales Volume Market Share by Countries in 2016
Table Middle East Neuroendocrine Tumor Drug Revenue (Million USD) by Countries (2012-2017)
Table Middle East Neuroendocrine Tumor Drug Revenue Market Share by Countries (2012-2017)
Figure Middle East Neuroendocrine Tumor Drug Revenue Market Share by Countries (2012-2017)
Figure Middle East Neuroendocrine Tumor Drug Revenue Market Share by Countries in 2016
Figure Saudi Arabia Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Israel Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure UAE Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Iran Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Neuroendocrine Tumor Drug Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Neuroendocrine Tumor Drug Sales (K Pcs) by Type (2012-2017)
Table Africa Neuroendocrine Tumor Drug Sales Market Share by Type (2012-2017)
Figure Africa Neuroendocrine Tumor Drug Sales Market Share by Type (2012-2017)
Figure Africa Neuroendocrine Tumor Drug Sales Market Share by Type in 2016
Table Africa Neuroendocrine Tumor Drug Sales (K Pcs) by Application (2012-2017)
Table Africa Neuroendocrine Tumor Drug Sales Market Share by Application (2012-2017)
Figure Africa Neuroendocrine Tumor Drug Sales Market Share by Application (2012-2017)
Table Africa Neuroendocrine Tumor Drug Sales Volume (K Pcs) by Countries (2012-2017)
Table Africa Neuroendocrine Tumor Drug Sales Market Share by Countries (2012-2017)
Figure Africa Neuroendocrine Tumor Drug Sales Market Share by Countries (2012-2017)
Figure Africa Neuroendocrine Tumor Drug Sales Market Share by Countries in 2016
Table Africa Neuroendocrine Tumor Drug Revenue (Million USD) by Countries (2012-2017)
Table Africa Neuroendocrine Tumor Drug Revenue Market Share by Countries (2012-2017)
Figure Africa Neuroendocrine Tumor Drug Revenue Market Share by Countries (2012-2017)
Figure Africa Neuroendocrine Tumor Drug Revenue Market Share by Countries in 2016
Figure South Africa Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Nigeria Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Egypt Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Algeria Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Table Eisai Neuroendocrine Tumor Drug Basic Information List
Table Eisai Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Eisai Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Eisai Neuroendocrine Tumor Drug Sales Market Share in EMEA (2012-2017)
Figure Eisai Neuroendocrine Tumor Drug Revenue Market Share in EMEA (2012-2017)
Table Exelixis, Inc. Neuroendocrine Tumor Drug Basic Information List
Table Exelixis, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Exelixis, Inc. Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Exelixis, Inc. Neuroendocrine Tumor Drug Sales Market Share in EMEA (2012-2017)
Figure Exelixis, Inc. Neuroendocrine Tumor Drug Revenue Market Share in EMEA (2012-2017)
Table Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Basic Information List
Table Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales Market Share in EMEA (2012-2017)
Figure Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Revenue Market Share in EMEA (2012-2017)
Table Hutchison MediPharma Limited Neuroendocrine Tumor Drug Basic Information List
Table Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales Market Share in EMEA (2012-2017)
Figure Hutchison MediPharma Limited Neuroendocrine Tumor Drug Revenue Market Share in EMEA (2012-2017)
Table Intezyne, Inc Neuroendocrine Tumor Drug Basic Information List
Table Intezyne, Inc Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Intezyne, Inc Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Intezyne, Inc Neuroendocrine Tumor Drug Sales Market Share in EMEA (2012-2017)
Figure Intezyne, Inc Neuroendocrine Tumor Drug Revenue Market Share in EMEA (2012-2017)
Table INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Basic Information List
Table INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales Market Share in EMEA (2012-2017)
Figure INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Revenue Market Share in EMEA (2012-2017)
Table Ipsen S.A. Neuroendocrine Tumor Drug Basic Information List
Table Ipsen S.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Ipsen S.A. Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Ipsen S.A. Neuroendocrine Tumor Drug Sales Market Share in EMEA (2012-2017)
Figure Ipsen S.A. Neuroendocrine Tumor Drug Revenue Market Share in EMEA (2012-2017)
Table Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Basic Information List
Table Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales Market Share in EMEA (2012-2017)
Figure Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Revenue Market Share in EMEA (2012-2017)
Table Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Basic Information List
Table Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales Market Share in EMEA (2012-2017)
Figure Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Revenue Market Share in EMEA (2012-2017)
Table Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Basic Information List
Table Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate (2012-2017)
Figure Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales Market Share in EMEA (2012-2017)
Figure Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Revenue Market Share in EMEA (2012-2017)
Table Midatech Pharma Plc. Neuroendocrine Tumor Drug Basic Information List
Table Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Basic Information List
Table MolMed S.p.A. Neuroendocrine Tumor Drug Basic Information List
Table Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Basic Information List
Table Novartis AG Neuroendocrine Tumor Drug Basic Information List
Table OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Basic Information List
Table OXiGENE, Inc. Neuroendocrine Tumor Drug Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Neuroendocrine Tumor Drug
Figure Manufacturing Process Analysis of Neuroendocrine Tumor Drug
Figure Neuroendocrine Tumor Drug Industrial Chain Analysis
Table Raw Materials Sources of Neuroendocrine Tumor Drug Major Manufacturers in 2016
Table Major Buyers of Neuroendocrine Tumor Drug
Table Distributors/Traders List
Figure EMEA Neuroendocrine Tumor Drug Sales (K Pcs) and Growth Rate Forecast (2017-2022)
Figure EMEA Neuroendocrine Tumor Drug Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Neuroendocrine Tumor Drug Price (USD/Pcs) and Trend Forecast (2017-2022)
Table EMEA Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Region (2017-2022)
Figure EMEA Neuroendocrine Tumor Drug Sales Market Share Forecast by Region (2017-2022)
Table EMEA Neuroendocrine Tumor Drug Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Neuroendocrine Tumor Drug Revenue Market Share Forecast by Region (2017-2022)
Table Europe Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Europe Neuroendocrine Tumor Drug Sales Market Share Forecast by Countries (2017-2022)
Table Europe Neuroendocrine Tumor Drug Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Neuroendocrine Tumor Drug Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Middle East Neuroendocrine Tumor Drug Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Neuroendocrine Tumor Drug Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Neuroendocrine Tumor Drug Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Africa Neuroendocrine Tumor Drug Sales Market Share Forecast by Countries (2017-2022)
Table Africa Neuroendocrine Tumor Drug Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Neuroendocrine Tumor Drug Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Type (2017-2022)
Figure EMEA Neuroendocrine Tumor Drug Sales Market Share Forecast by Type (2017-2022)
Table EMEA Neuroendocrine Tumor Drug Sales (K Pcs) Forecast by Application (2017-2022)
Figure EMEA Neuroendocrine Tumor Drug Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources